Fibroid cell proliferation

Fibroid cell proliferation refers to the pathological expansion of smooth muscle cells and fibroblasts within the myometrium, resulting in the formation of benign tumors known as uterine leiomyomas or fibroids [NIH: Uterine Fibroids, 2022]. This process is not a single molecular target but a complex phenotypic outcome driven by the dysregulation of various signaling pathways, most notably those mediated by the steroid hormones estrogen and progesterone [PubMed: PMCID PMC3742611]. These hormones act via their respective nuclear receptors to induce growth factors like TGF-beta and activate the MAPK and PI3K/Akt pathways, leading to excessive extracellular matrix deposition and cellular hyperplasia [StatPearls: Uterine Leiomyoma, 2023]. Approximately 70% of these proliferative clusters harbor mutations in the MED12 gene, which is a key driver in the initiation of fibroid growth. Pharmacological intervention focuses on suppressing the hormonal environment that sustains proliferation, using agents like GnRH agonists/antagonists or selective progesterone receptor modulators to induce cell cycle arrest and volume reduction [PubMed: PMID 23514710]. While technically a biological process rather than a discrete therapeutic receptor, reducing fibroid cell proliferation remains the primary clinical objective for treating symptomatic leiomyomas.

Other names

Uterine leiomyoma growthLeiomyoma cell proliferationUterine fibroid hyperplasiaMyometrial cell proliferation

Drugs typically address this process by inhibiting the hormonal pathways (estrogen and progesterone) that drive it, such as through GnRH receptor antagonism or selective progesterone receptor modulation (SPRM) [StatPearls: Uterine Leiomyoma, 2023].